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1684-1182/Copyright ª 2014, TaiwanBackground: Central line-associated bloodstream infection (CLABSI) is a serious complication
in hematologyeoncology patients. This study aimed to analyze the prevalence of CLABSI and
the effectiveness of antimicrobial lock therapy (ALT) in pediatric patients.
Methods: BSIs of all pediatric hematologyeoncology patients admitted to a children’s hospital
between January 2009 and December 2013 were reviewed. The United States National Health-
care Safety Network and Infectious Diseases Society of America guidelines were used to define
CLABSI and catheter-related BSI (CRBSI). The incidence, laboratory and microbiology charac-
teristics, poor outcome, and effectiveness of ALT were analyzed.
Results: There were 246 cases of CLABSI in 146 patients (mean age, 10.0 years), including 66
(26.8%) cases of CRBSI. The incidence of CLABSI was 4.49/1000 catheter-days, and theediatric Infectious Diseases, Department of Pediatrics, National Taiwan University Hospital, College of
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640 H.-C. Tsai et al.infection was responsible for 32.9% of the complications these patients developed and 9.3% of
contributable mortality. Patients with acute myeloid leukemia had the highest infection den-
sity (5.36/1000 patient-days). Enterobacteriaceae (40.2%) and coagulase-negative staphylo-
cocci (CoNS; 20.7%) were the predominant pathogens. In multivariate analysis, older age,
male sex, elevated C-reactive protein, acute lymphoblastic leukemia, and candidemia were
associated with poor outcome. The success rate of ALT was 58.6% (17/29) for the treatment
of CoNS and 78.3% (29/37) for Enterobacteriaceae infections. Patients with candidemia
(n Z 18) had the highest mortality (33.4%) and catheter removal rate (66.7%). Chlorhexidine
as the disinfectant decreased the 1-year CLABSI rate from 13.7/1000 to 8.4/1000 catheter-
days (p Z 0.02).
Conclusion: CoNS and Enterobacteriaceae are the predominant pathogens in CLABSI among pe-
diatric hematologyeoncology patients. ALT is effective and showed no significant side effect.
New disinfection practice and infection control measures can decrease CLABSI.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
In pediatric hematologyeoncology patients, the central
venous catheter, especially totally implantable venous
access ports (Port-A), is important for the administration of
antineoplastic chemotherapy, blood component therapy,
and parenteral nutrition. It is also useful for blood sam-
pling. The most common and serious complication is central
line-associated bloodstream infection (CLABSI) or catheter-
related BSI (CRBSI). The most commonly involved organisms
are coagulase-negative staphylococci (CoNS), Staphylo-
coccus aureus, Enterococcus spp., Escherichia coli, Klebsi-
ella spp., other enteric Gram-negative bacteria, and
Candida spp.,1 with infection rates varying widely in
different patient groups.
In adults, 5.6e8.0% of patients with Port-A catheter
experience a related infection, with the incidence rate
ranging from 0.15 to 0.39/1000 catheter-days.1e4 However,
there is a lack of similar data in the pediatric
group. An estimated 0.2 episodes/1000 catheter-days in
children with sickle cell disease and 11 episodes/1000
catheter-days in infants with intestinal insufficiency have
been reported.5,6
The diagnosis of CRBSI is based on the culture of the
removed catheter tips or on quantitative blood cultures
drawn from the catheter and from peripheral veins. The
incidence of CRBSI is difficult to evaluate because of the
need to obtain blood samples in pairs in the pediatric
group. Antimicrobial lock therapy (ALT), also called anti-
infective lock therapy or antibiotic lock therapy involves
instilling an antibiotic or antiseptic into the catheter lumen
to permit high concentration at the site of infection, is a
novel way of treating CLABSI while attempting to salvage
the catheter.1,7 Performing ALT early to save the catheter
or avoid unnecessary systemic treatment is valuable,
especially in the pediatric group. The Infectious Diseases
Society of America treatment guidelines for CRBSI recom-
mend the routine use of adjunctive ALT for adults and
children.8 This retrospective study analyzed the incidence,
laboratory and microbiology characteristics, risk factors,
and outcomes in CLABSI/CRBSI episodes, and the effec-
tiveness of ALT in pediatric hematologyeoncology patients.Methods
Patients and setting
This study was conducted in a university-teaching pediatric
hospital in Taipei, Taiwan, with 292 beds. Pediatric hema-
tologyeoncology in-patients, aged 0e18 years, with central
venous catheter who had a BSI from January 2009
to December 2013 in the oncology department were
enrolled. Patients with BSI with other identified infectious
foci were excluded. The data retrieved from the medical
records included sex, age at the infection day, hema-
tologicaleoncological diseases, date of central venous
catheter implantation and removal, white blood cell count,
neutropenia (absolute neutrophil count < 500/mm3), level
of C-reactive protein (CRP), microbiology results of all clin-
ical specimens, use of systemic antimicrobial therapy, and
the duration and regimen of ALT for documented infections.
Disinfection methods
For central line entry-site care, topical skin disinfection
with povidoneeiodine swabs and dry gauze dressing were
used weekly or whenever the dressing is soiled or loose.
Since June 2012, 2% chlorhexidine (in 70% alcohol) was used
as the disinfectant as recommended by the U.S. Centers for
Disease Control and Prevention guideline.9
Patient management and follow up
In the hematologyeoncology departments, the primary
physicians were encouraged to obtain blood samples (at
least 1 mL) for culture from the central line catheter and
peripheral veins in pairs when the patients had clinical
symptoms or signs of infection, fever > 38.3C, or unstable
vital signs (e.g., hypotension, tachypnea, tachycardia/
bradycardia, or consciousness change). Samples from other
potential infection foci were also cultured to determine the
origin of infection. Empirical antibiotics were administered
after obtaining blood cultures and their doses were
adjusted based on the culture results. When CRBSI or a
Table 2 Clinical characteristics of patients with central
line-associated bloodstream infection
Characteristic Values
Age, y, median (IQR) 10 (4.8e14)
Male, n (%) 151 (M:F Z 1.58:1)
WBC cells/mm3, median (IQR) 360 (100e2210)
CRP level, mg/L, median (IQR) 3.50 (1.04e7.97)
Neutropenia, n (%) 184 (74.8%)
Paired blood culture, n (%) 219 (89%)
Polymicrobial infection, n (%) 28 (11.3%)
CRBSI 66 (26.8%)
Catheter type
Port-A 214
Temporary nontunneled CVC 30
Hickman 2
Duration from catheter insertion
day to DOIa, median (IQR)
134 (25e310.3)
Poor outcome, n (%) 81 (32.9)
Contributable mortality, n (%) 23 (9.3)
Catheter removal, n (%) 66 (26.8)
Successful ALT in CRBSI/catheter
infection
58/81 (71.6)
a DOI is defined as the 1st day of clinical suspicion of infection
(i.e., day of infection).
N Z 246 episodes.
ALT Z antimicrobial lock therapy; CRBSI Z catheter-related
bloodstream infection; CRP Z C-reactive protein;
CVC Z central venous catheter; IQR Z interquartile range;
WBC Z white blood cell.
Table 3 Underlying diagnosis in pediatric hema-
tologyeoncology patients with central line-associated
bloodstream infection
Underlying diagnosis Number/
percentage
Infection
densitya(0/00)
Acute lymphoblastic 90 (36.6) 3.63
ALT in pediatric hematologyeoncology patients with CLABSI 641central venous catheter infection was documented, ALT
was initiated under the supervision of an infectious diseases
specialist. Patients with uncertain episodes of CRBSI (i.e.,
no confirmed diagnosis of CRBSI was made) or central
venous catheter infection who received ALT were excluded
from the analysis.
The ALT technique involved instilling a concentrated
antibiotic solution (5e10 mL) diluted with sterile normal
saline and heparin (50 U) into the catheter lumen for at
least 12 hours daily for 10e14 days. The antibiotic solution
was withdrawn before the administration of other intra-
venous therapies. The most frequently used antibiotics for
ALT are listed in Table 1.8,10e13 Serial follow-up blood cul-
ture was obtained 24, 48, 72, and 120 hours, and 2 days
after ALT from both peripheral veins and central catheters.
If the catheter was removed, its tip was sent for culture.
The primary physician determined whether to remove the
central catheter based on clinical severity, the identified
pathogen, and responses to antibiotic treatment. Data from
the personal medical record and hospital infection control
center were reviewed. Data on catheter-day were elec-
tronically recorded and available since 2011.
Definitions
CLABSI14 was defined as one of the following in a patient
with central line catheter: (1) at least one set of positive
blood culture of recognized pathogens, including Enter-
obacteriaceae or other Gram-negative bacilli, S. aureus,
and fungi, without other identifiable infectious foci; or (2)
at least two sets of positive blood cultures of bacteria that
were potential skin contaminants, including CoNS, Viridans
streptococci, Propionibacterium spp., Bacillus spp., or
micrococci, together with clinical signs (i.e., fever > 38C,
chills, or hypotension). Repeated positive blood cultures
with the same pathogen were considered a single episode
of CLABSI if the two sets of blood cultures were obtained
within 1 week (for bacterial pathogens) or within 2 weeks
(for fungal pathogens).
Patients with CRBSI8 were defined as those with clinical
signs of infection and the same microorganism grown from
at least one percutaneous blood culture and from a culture
of the catheter tip (>15 colony-forming units), or a growth
of microbes from blood sample drawn from a catheter hub
at least 2 hours before microbial growth was detected in a
blood sample obtained from a peripheral vein. If the cul-
ture was positive only from the central venous catheter
sample, it was defined as central catheter infection.Table 1 Frequently used antimicrobials and their con-
centrations used in antimicrobial lock therapy in pediatric
hematologyeoncology patients
Vancomycin: 5 mg/mL Teicoplanin: 10 mg/mL
Amikacin: 2 mg/mL Gentamicin: 10 mg/mL
Minocycline: 1 mg/mL Erythromycin: 5 mg/mL
Ciprofloxacin: 1 mg/mL Amphotericin B: 2.5 mg/mL
Ampicillin: 2 mg/mL
Cefazolin: 5 mg/mL
Ceftazidime: 5 mg/mL
The data presented are modified from references 8,10e13.The infection density was estimated as number of epi-
sodes/1000 patient-days and number of episodes/1000
catheter-days. The CLABSI and CRBSI density data were
available in the health information system of the hospital
from 2009 to 2013 and from 2011 to 2013, respectively.
The success of ALT was defined as “no positive culture”
of the same pathogen after 72 hours of therapy. Relapse
was defined as the culture of the same pathogen in bloodleukemia
Acute myeloid leukemia 66 (26.8) 5.36
Neuroblastoma 23 (9.3) 2.31
Lymphoma 10 (4.0) 1.05
Germ cell tumor 8 (3.3) 1.76
Rhabdomyosarcoma 6 (2.4) 1.64
Osteosarcoma 6 (2.4) 1.12
Severe aplastic anemia 9 (3.6) 2.67
Langerhan histiocytosis 4 (1.6) 3.61
Medulloblastoma 7 (2.8) 3.97
Other malignancies 17 (6.7) NA
a Infection density: episodes/1000 patient-day of specified
diagnosis.
Figure 1. Distribution of central line-associated blood-
stream infection (CLABSI) according to interval between date
of infection (DOI) and catheter insertion.
Table 4 Factors significantly associated with poor outcome in pediatric hematologyeoncology patients with central line-
associated bloodstream infection
Unadjusted OR (95% CI) p Adjusted OR (95% CI) p
Older age 4.24 (2.40e7.51) <0.001 1.10 (1.04e1.16) 0.001
Male sex 2.13 (1.19e3.79) 0.010 2.11 (1.06e4.22) 0.034
Neutropenia 3.49 (1.62e7.53) 0.001 2.18 (0.88e5.39) 0.091
Elevated CRP 1.07 (1.04e1.11) <0.001 1.06 (1.02e1.11) 0.001
ALL 2.18 (1.26e3.77) 0.005 2.51 (1.30e4.86) 0.006
Candidemia 12.27 (3.44e43.80) <0.001 7.75 (2.02e29.78) 0.002
ALL Z acute lymphoblastic leukemia; CI Z confidence interval; CRP Z C-reactive protein; OR Z odds ratio.
642 H.-C. Tsai et al.sample within 3 months. Patients with poor outcome were
those with shock, sepsis15 [defined as suspected or proven
infectious etiology with systemic inflammatory response
syndrome, involving 2 of the following 4 items: fever or
hypothermia (>38.5 or <36C), tachycardia, tachypnea,
and elevated leukocyte count or depressed for age or >10%
immature neutrophils], hematogenous complications (i.e.,
infective endocarditis, septic arthritis, or vertebral osteo-
myelitis), septic thrombophlebitis, respiratory failure, and
intensive care unit transfer. Attributable mortality was
confirmed from the death certificate, which was applied by
the clinician following the death of the patient.
Statistical analysis
Descriptive statistics included frequencies and percentages
for categorical variables, and medians and interquartile
ranges (IQRs) for continuous variables. Potential risk factors
associated with poor outcome were analyzed by univariate
analysis. Multivariate analysis was conducted using a step-
wise logistic regression model to identify the set of inde-
pendent risk factors. Statistical significance was set at
p < 0.05. Statistical analysis was performed using the SPSS
software package version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
There were 279 BSI episodes in 157 pediatric hema-
tologyeoncology patients between January 2009 and
December 2013. Among these, 246 (88.18%) CLABSI episodes
were documented and 66 (26.8%) were classified as CRBSI.
Other excluded episodes were secondary to urinary tract
infection (n Z 6), soft-tissue infection (n Z 7), intra-
abdominal infection (n Z 3), pneumonia (n Z 5), mastoid-
itis (n Z 1), and bacteremia or fungemia without central
venous catheter and other obvious foci (n Z 11).
The characteristics of CLABSI episodes are summarized in
Table 2. Themedian patient age was 10.0 years (IQR, 4.8e14
years) and the male-to-female ratio was 1.6:1.
There were 214 Port-A-related episodes, two Hickman-
related episodes, and 30 temporary nontunneled central
venous catheter-related episodes. Paired blood cultures
were obtained from both peripheral veins and central
venous catheter in 89% (219/246) of CLABSI episodes. The
median CRP was 3.50 mg/dL (IQR, 1.04e7.97). Neutropenia
occurred in 184 (74.8%) episodes. Polymicrobial pathogenaccounted for 11.3% (28/246) of these episodes. Acute
leukemia (63.4%, 156/246) was the leading underlying dis-
ease, followed by neuroblastoma (9.3%, 23/246) and lym-
phoma (4.0%, 10/246). Patients with acute myeloid
leukemia (AML) had the highest infection density (5.36
episodes/1000 patient-days; Table 3). In multivariate
analysis, older age, male sex, acute lymphoblastic leuke-
mia (ALL), elevated CRP, and candidemia were associated
with poor outcome (Table 4). Meanwhile, white blood cell
count, diagnosis other than ALL, and receiving bone marrow
transplant and ALT were not associated with poor outcome.
Themedian duration from catheter insertion to the day of
infection (DOI) was 134 days (IQR, 25e310.3 days; nZ 232,
missing data 14). Of the CLABSI episodes, 29% occurred
within 30 days after the catheter implantation (Figure 1).
Microbiological data and clinical management
The microbiological data are summarized in Table 5. The
predominant pathogens were Enterobacteriaceae (40.2%)
and CoNS (20.7%). Most infections were monomicrobial
(88.6%). Methicillin resistance was noted in 94.1% (48/51) of
CoNS cases and in 20% (2/10) of S. aureus cases.
The average period from the DOI to initiating ALT is 1.96
days. The success rate of ALT as a catheter salvage man-
agement was 58.6% (17/29) in cases with CoNS infections,
78.0% (29/37) in Enterobacteriaceae, and 66.7% (2/3) in S.
aureus, and none in Candida spp. The percentage of central
catheter removal was highest in Candida cases (66.7%; 12/
Table 5 Analysis of microbiological data in the 246 central line-associated bloodstream infection episodes in pediatric
hematologyeoncology patients
Number (%) Removal
catheter (%)
Contributory
mortality (%)
CRBSI
(ALT number)
Catheter
infection
(ALT number)
Number of
successful
ALT (%)
Relapse rate
in 3 mo (%)
Coagulase-negative
staphylococci, n (%)
51 (20.7) 25 (49.0) 4 (7.8) 30 (16) 17 (13) 17 (58.6) 3 (17.6)
Viridans
streptococci, n (%)
18 (7.3) 1 (5.6) 0 (0) 3 (3) 0 (0) 2 (66.7) 0 (0)
Staphylococcus
aureus, n (%)
10 (4.1) 5 (50) 1 (10) 3 (3) 3 (0) 2 (66.7) 0 (0)
Enterococcus spp., n (%) 15 (6.1) 3 (20) 2 (13.3) 1 (0) 5 (3) 1 (33.3) 1 (100)
Bacillus spp., n (%) 3 (1.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other GPC, n (%) 5 (2.0) 1 (20) 2 0 (0) 0 (0) 0 (0) 0 (0)
Enterobacteriaceae, n (%) 99 (40.2) 13 (13.1%) 7 (7) 20 (17) 21 (20) 29 (78.0) 2 (6.9)
Escherichia coli 47 6 3 10 (7) 10 (8) 13 1
Klebsiella spp. 41 8 4 8 (7) 9 (7) 11 1
Proteus mirabilis 1 0 1 0 (0) 0 (0) 0 (0) 0 (0)
Enterobacter cloacae 7 1 1 3 (3) 0 (0) 2 0 (0)
Serratia 3 1 0 (0) 0 (0) 2 (2) 1 0 (0)
Morganella morganii 1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Citrobacter freundii 1 0 (0) 0 (0) 0 (0) 1 (1) 1 0 (0)
Salmonella spp. 6 0 (0) 0 (0) 2 (2) 0 (0) 2 0 (0)
Pseudomonas aeruginosa 10 1 2 0 (0) 0 (0) 0 (0) 0 (0)
Stenotrophomonas
maltophilia
5 1 2 1 (1) 1 (1) 1 0 (0)
Burkholderia cepacia 1 1 0 (0) 1 (1) 0 (0) 1 0 (0)
Sphigomonas spp. 2 2 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Acinetobacter spp.a 11 (4.5) 3 (27.3) 0 (0) 6 (5) 3 (1) 6 (100) 0 (0)
Other GNB 9 (3.7) 1 (11.1) 0 (0) 0 (0) 3 (3) 2 (66.7) 0 (0)
Candida spp., n (%) 18 (7.3) 12 (66.7) 6 (33.4) 5 (2) 4 (0) 0 (0) 0 (0)
C. albicans 3 1 2 5 0 (0) 0 (0) 0 (0)
C. tropicalis 12 9 3 0 (0) 4 (2) 0 (0) 0 (0)
C. parapsilosis 2 1 0 0 (0) 0 0 (0) 0 (0)
C. krusei 1 1 1 0 (0) 0 0 (0) 0 (0)
Other fungi 2 (0.8) 1 (50) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
a Acinetobacter baumannii and Acinetobacter lwoffii.
ALT Z antimicrobial lock therapy; CRBSI Z catheter-related bloodstream infection.
Other GNB: Aeromona spp. (n Z 3), Moraxella spp. (n Z 1), Haemophilus parainfluenzae (n Z 1), Alcaligenes faecalis (n Z 1),
Rhizobium radiobacter (n Z 1), Achromobacter xylosoxidans (n Z 1), and Capnocytophaga species (n Z 1).
Other fungi: Fusarium species (n Z 1) and Trichosporon asahii (n Z 1).
Other GPC: Rothia mucilaginosa (n Z 1), Gordonia spp. (n Z 1), Granulicatella adiacens (n Z 1), Corynebacterium jeikeium (n Z 1),
and Leuconostoc species (n Z 1).
ALT in pediatric hematologyeoncology patients with CLABSI 64318), followed by S. aureus (50%; 5/10) and CoNS (49%; 25/
51). The mortality rates were higher among cases with
Candida infections (33.4%), but modest in cases with CoNS
and Enterobacteriaceae infections (7.8% and 7.0%,
respectively).
The overall incidence of CLABSI and CRBSI was 4.49 and
1.08/1000 catheter-day, respectively. In terms of the
annual distribution of various pathogens in CLABSI
(Figure 2), the percentage of CoNS peaked in 2010
(Figure 3), resulting from an outbreak in mid-2010 to early
2011. As a result of timely infection control intervention
and the use of chlorhexidine as a disinfectant since June
2012, the incidence of CLABSI decreased gradually, espe-
cially in the CoNS group (Figures 3 and 4). The 1-year CLABSI
rates decreased significantly after chlorhexidine use (from
13.7/1000 to 8.4/1000 catheter-days; p Z 0.02).Discussion
In this study, the CLABSI mortality and catheter removal
rates were 9.3% and 26.8%, respectively, in pediatric
hematologyeoncology patients in Taiwan, which are similar
to an earlier report from Turkey.16 Patients with AML have
the highest infection density (5.36 episodes/1000 patient-
days). Rinke et al reported that a diagnosis of AML is
significantly associated with ambulatory CLABSI in the pe-
diatric oncology group.17 More intensive chemotherapy
regimen and prolonged periods of neutropenia accompa-
nying AML may be the underlying causes.
The predominant pathogens found in our study were
CoNS and Enterobacteriaceae, similar to that of the adult
patient group.2 In the CRBSI group, CoNS accounts for 45.5%
of infections (30/66). Intraluminal colonization of the
Figure 2. Microbiologic distribution for central line-
associated bloodstream infection (CLABSI) in pediatric hema-
tologyeoncology patients in 2009e2013. Enterobacteriaceae
and coagulase-negative staphylococci (CoNS) were the pre-
dominant pathogens. GNB Z Gram-negative bacilli;
GPC Z Gram-positive coccus.
Figure 4. Central line-associated bloodstream infection
(CLABSI) density decreased gradually in the period 2009e2013.
CoNS Z coagulase-negative staphylococci.
644 H.-C. Tsai et al.common skin flora from repeated puncture through the
septum may account for the high percentage of CoNS.8 In
this study, the prevalence of CoNS in CLABSI has decreased
gradually in 2012e2013. The use of chlorhexidine as a
disinfectant and the promotion of central venous catheter
bundle care may have contributed to this decrease.18 Kao
et al also reported that topical skin disinfection with
chlorhexidine may prevent Port-A-related BSI caused by
Gram-positive bacteria in adult patients with solid
cancers.19
The median duration from catheter insertion to the date
of catheter infection is 134 days, with IQR of 25e310.3
days. Of all the CLABSI episodes, 29.6% (68/230) occurred
within 30 days of central venous catheter insertion
(Figure 1). Another study also showed that episodes of Port-
A BSI mostly take place during the first 6 months in children
with acute leukemia,20 which may be related to the more
profound immune suppression at this stage due to intensive
chemotherapy. In addition, unfamiliarity of the patients orFigure 3. Central line-associated bloodstream infection
(CLABSI) episodes/1000 patient-days of the coagulase-negative
staphylococci (CoNS) group and the non-CoNS group in
2009e2013.caregivers with catheter care during the early periods of
central venous catheter insertion may also contribute to
high infection rates. Thus, to reduce the CLABSI rate,
comprehensive education on catheter care and self-
hygiene for the patients and their caregivers before and
right after catheter insertion is extremely important.
All BSIs in patients with a central venous catheter but
without evidence of other infectious foci are considered as
CLABSI. Data from pediatric oncology patients showed that
only about one third of CLABSI episodes are related to in-
fections from other sites,1,21 suggesting that two thirds of
CLABSI episodes may be related to central catheters.
However, such a clinical surveillance definition may lead to
overestimation of infections truly associated with central
venous catheters. In this study, only 28.7% of CLABSI epi-
sodes were confirmed as CRBSI. The CRBSI rate in this study
was 1.08/1000 catheter-days, which is comparable to pre-
vious studies in the pediatric group (0.5e6.75/1000 cath-
eter-days).20,22e28 To diagnose CRBSI, obtaining blood
samples simultaneously from peripheral veins and the
central catheter is crucial.
The Infectious Diseases Society of America treatment
guidelines for CLABSI recommend the use of adjunctive ALT
for adults and children. In a systemic review and meta-
analysis in 2011, O’Horo et al7 reported that the combina-
tion of systemic antibiotics and culture-guided lock therapy
is superior to systemic antibiotics alone, with 10% of locked
patients requiring replacement compared with 33% of pa-
tients without lock. However, the use of ALT is not consis-
tent in the pediatric group, which may be related to the
paucity of pediatric safety data, the potential for heparin
overdose, and the limited range of studied antibiotics.1 De
Sio et al successfully used an antibiotic lock technique with
vancomycin in combination with urokinase in 10 pediatric
cancer patients with Gram-positive catheter-related
bacteremia after treatment with appropriate intravenous
antibiotics was found to be ineffective.29 Our results show
there were no severe side effects after ALTwas widely used
in 2009. The overall success rate was 71.6%. Therefore, ALT
could be considered as a routine therapy for pediatric
hematologyeoncology patients with CRBSI.
Factors associated with poor ALT response were also
identified in this study. CLABSI patients with older age,
elevated CRP, ALL, or candidemia have poor outcome.
Although very few patients with candidemia received ALT in
this study, the high mortality and failure rates of ALT in
ALT in pediatric hematologyeoncology patients with CLABSI 645these patients were compatible with data mentioned in the
current guidelines.8,30
Although the total CLABSI rate decreased during the study
period, longer follow up is still warranted. Future strategies
must be focused on decreasing CRBSI. Chlorhexidine-
impregnated sponge dressing or antimicrobial/antiseptic-
impregnated catheters may be a choice for the pediatric
group.9,31
In conclusion, CLABSI is a serious complication in pedi-
atric hematologyeoncology patients with central line
catheter, and was responsible for 9.3% of the patient
deaths in this study. CoNS and Enterobacteriaceae are
the predominant pathogens. Current disinfection practice
and infection control measures may decrease CLABSI.
Besides, routine ALT based on culture results is a safe and
effective option for catheter salvage therapy in pediatric
hematologyeoncology patients.Conflicts of interest
All contributing authors declare no conflicts of interest.References
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